Beam Therapeutics (BEAM) Shares Outstanding (Diluted Average) (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $103.3 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 17.38% year-over-year to $103.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.3 million (up 17.38% YoY) and the FY2025 annual result came in at $98.9 million, up 20.16% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $103.3 million in Q1 2026 per BEAM's latest filing, from $98.9 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $103.3 million in Q1 2026 and bottomed at $68.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $81.7 million (2024), against an average of $82.2 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) climbed 5.2%; it then increased 24.38% in 2025.
• Tracing BEAM's Shares Outstanding (Diluted Average) over 5 years: stood at $70.0 million in 2022, then advanced by 10.19% to $77.2 million in 2023, then climbed by 6.69% to $82.3 million in 2024, then climbed by 20.16% to $98.9 million in 2025, then rose by 4.4% to $103.3 million in 2026.
• Per Business Quant, the three latest BEAM Shares Outstanding (Diluted Average) figures stand at $103.3 million (Q1 2026), $98.9 million (Q4 2025), and $97.6 million (Q3 2025).

Peer Comparison